Transcutaneous pO₂ monitoring in the pediatric intensive care unit
COMPARISON OF TRANSCUTANEOUS PCO₂ AND PO₂ MEASUREMENTS WITH ARTERIAL BLOOD GAS ANALYSIS IN PEDIATRIC INTENSIVE CARE PATIENTS: IS TRANSCUTANEOUS pO₂ A RELIABLE ALTERNATIVE?
We will test whether noninvasive skin sensors that measure oxygen and carbon dioxide give similar results to arterial blood gases in children in the PICU.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 1 Month to 18 Years |
| Sex | All |
| Sponsor | Istanbul Medeniyet University Academic / other |
| Locations | 1 site (Istanbul, Kadıkoy) |
| Trial ID | NCT07478380 on ClinicalTrials.gov |
What this trial studies
This is an observational cohort study that collects paired transcutaneous and arterial blood gas measurements from PICU patients who already have arterial lines in place. Paired readings are obtained simultaneously during routine clinical care to minimize timing differences. Agreement between transcutaneous pO₂/pCO₂ and arterial PaO₂/PaCO₂ will be analyzed using correlation and Bland-Altman methods to quantify bias and limits of agreement. The focus is whether transcutaneous pO₂ can reliably substitute for invasive arterial sampling in critically ill children.
Who should consider this trial
Good fit: Children aged 1 month to 18 years admitted to the PICU who have an arterial catheter and can tolerate transcutaneous sensor placement while hemodynamically stable are ideal candidates.
Not a fit: Children with severe skin disease or burns at sensor sites, severe peripheral perfusion impairment or high-dose vasopressor support, or those lacking paired arterial sampling are unlikely to benefit.
Why it matters
Potential benefit: If reliable, transcutaneous monitoring could reduce painful arterial blood draws and provide continuous, noninvasive oxygen and CO2 monitoring for PICU patients.
How similar studies have performed: Prior work in neonates and stable pediatric populations shows mixed accuracy for transcutaneous pO₂/pCO₂ and data in critically ill children are limited and inconsistent.
Eligibility criteria
Show full inclusion / exclusion criteria
Eligibility Criteria Inclusion Criteria: * Age between 1 month and 18 years * Admission to the Pediatric Intensive Care Unit (PICU) * Presence of an arterial catheter allowing arterial blood gas (ABG) sampling * Simultaneous or paired transcutaneous pCO₂ and pO₂ monitoring available * Hemodynamically stable at the time of measurement Exclusion Criteria: * Severe skin disease, burns, or local skin infection at the transcutaneous sensor site * Severe peripheral perfusion impairment (e.g., refractory shock or high-dose vasopressor support) * Congenital or acquired conditions interfering with accurate transcutaneous measurements * Technical failure or inability to obtain reliable transcutaneous readings * Missing or incomplete paired ABG-transcutaneous measurement data
Where this trial is running
Istanbul, Kadıkoy
- Göztepe Prof. Dr. Süleyman Yalçın City Hospital — Istanbul, Kadıkoy, Turkey (Türkiye) (Recruiting)
Study contacts
- Study coordinator: Ayşe Aşık, MD
- Email: drayseasik@gmail.com
- Phone: +905533280449
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.